热门资讯> 正文

Tempus获得FDA批准Tempus ECG-Low EF

2025-07-16 23:19

Tempus AI (NASDAQ:TEM) said that it has obtained 510((k)) clearance from the U.S. FDA for Tempus ECG-Low EF software.
This software utilizes artificial intelligence to help identify patients who may be experiencing a low left ventricular ejection fraction, a measure of heart function.
With this new clearance, Tempus ECG-Low EF becomes the second AI-powered ECG device approved by the FDA of the company, following the earlier approval of Tempus ECG-AF.

More on Tempus AI

Tempus AI: High-Growth And High-Risk
Tempus AI Is Well Worth Its Price Tag
I'm Still Bullish On Tempus AI
Personalis expands Tempus deal to include colorectal cancer testing
Tempus AI proposes $400M convertible debt offering

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。